TME composition is generally recognized as a crucial parameter for the efficacy of ICIs, but biological data, especially for the patients with NSCLC with uncommon EGFR or ERBB2 mutations, are scarce.16 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.